• Vertiv, Pure Storage, And More: News From August 2020

    Bio-IT World   August featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including Vertiv, Pure Storage, and more.

    Aug 25, 2020

  • Beetle Viruses, Nitrate Supplements, Missing Sense of Smell: COVID-19 Updates

    Bio-IT World | How a beetle virus is informing SARS-CoV-2 research, plus nitrate supplementation for aid breathing, new small molecules active against the virus, and a theory for why COVID-19 patients lose their sense of smell. Plus, $9.8 million from DOD for vaccine research and virus-like particles for vaccine development.

    Aug 21, 2020

  • Combined Monogenic, Polygenic Risk Scores Could Change Medical Understanding of Disease

    Bio-IT World | In a paper published today in Nature Communications, IBM and the Broad Institute reported the first results of their collaboration to develop predictive models for cardiovascular disease.

    Aug 20, 2020

  • Bringing Peer Review To Early COVID-19 Research, More News

    Bio-IT World | New insights into the SARS-CoV-2 spike protein, a daily aerosol protectant, a look a death rates in 1918 and now, and a journal dedicated to publishing COVID-19 research with visible peer review. Plus new funding from NIH and the American Heart Association to enable further research on SARS-CoV-2 and COVID-19.

    Aug 18, 2020

  • Bringing Peer Review To Early COVID-19 Research, More

    Bio-IT World | New insights into the SARS-CoV-2 spike protein, a daily aerosol protectant, a look a death rates in 1918 and now, and a journal dedicated to publishing COVID-19 research with visible peer review. Plus new funding from NIH and the American Heart Association to enable further research on SARS-CoV-2 and COVID-19.

    Aug 14, 2020

  • Five Steps to Commercialization Success and Common Challenges You Can Easily Avoid

    Bio-IT World Contributed Commentary | It’s no surprise that advancements in novel technologies and the advent of big data have propelled significant breakthroughs in pharmaceutical development. The last decade has not only seen an increase in new chemical and biological entities but also significantly more innovative medicines reaching the market. Looking to the future, we also expect to see an intensified focus on neglected diseases as new and emerging biopharma companies (EBP) drive new medicine launches. However, to get there, organizations reaching for “first-in-market” status or securing key market areas depends on their ability to swiftly commercialize these new technologies and therapeutics.

    Aug 17, 2020